

REVIEW ARTICLE

Julie R. Ingelfinger, M.D., *Editor*

Contrast-Associated Acute Kidney Injury

Roxana Mehran, M.D., George D. Dangas, M.D., Ph.D.,
and Steven D. Weisbord, M.D.

From the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York (R.M., G.D.D.); and the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh School of Medicine, Pittsburgh (S.D.W.). Address reprint requests to Dr. Mehran at the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl., New York, NY 10029, or at roxana.mehran@mountsinai.org.

N Engl J Med 2019;380:2146-55.
DOI: 10.1056/NEJMra1805256

Copyright © 2019 Massachusetts Medical Society.

CONTRAST-ASSOCIATED ACUTE KIDNEY INJURY IS CHARACTERIZED BY A decrease in kidney function that occurs within days after the intravascular administration of iodinated contrast material. In the 1950s, initial cases were reported in patients with preexisting kidney disease who were undergoing intravenous pyelography with contrast agents that were associated with a high incidence of acute kidney injury and other adverse effects.¹⁻⁴ Over time, an evolution in the design of contrast agents, improved recognition of risk factors, and implementation of preventive care resulted in lower rates of acute kidney injury after the administration of contrast material⁵⁻⁷ (Fig. 1). More recent studies have suggested that the risk of acute kidney injury due to contrast material is overestimated.⁹⁻¹³ Such studies are important, considering that angiographic procedures may be underused in patients with chronic kidney disease who present with conditions such as acute coronary syndromes, presumably because of concern about precipitating acute kidney injury.¹⁴ This review summarizes the pathophysiology of contrast-associated acute kidney injury, the diagnostic criteria, and risk stratification; discusses current controversies regarding the incidence of this condition; and highlights studies that have provided the evidence that forms the basis for preventive care.

PATHOPHYSIOLOGY, DEFINITION, AND RISK ESTIMATION

Although the pathophysiological mechanisms by which contrast agents cause kidney injury have not been completely elucidated, direct and indirect effects, as well as hemodynamic perturbations, have been implicated^{15,16} (Fig. 2). Contrast agents are directly toxic to tubular epithelial cells, leading to loss of function and both apoptosis and necrosis. Indirect mechanisms are related to ischemic injury due to vasomotor changes mediated by vasoactive substances such as endothelin, nitric oxide, and prostaglandins. The outer renal medulla has a relatively low partial pressure of oxygen, which when coupled with enhanced metabolic demand, makes the medulla particularly susceptible to the hemodynamic effects of contrast material.¹⁷

Historically, the decline in kidney function after the intravascular administration of iodinated contrast material was referred to as contrast-induced nephropathy and commonly defined as an increase in the plasma creatinine level of at least 0.5 mg per deciliter (44 μ mol per liter) or at least a 25% increase from the baseline level within 2 to 5 days after exposure to contrast material.¹⁸⁻²¹ The Kidney Disease Improving Global Outcomes (KDIGO) working group proposed the term “contrast-induced acute kidney injury” and suggested a definition based on a plasma creatinine level that has increased by a factor of 1.5 times or more over the baseline value within 7 days after exposure to contrast medium, a plasma creatinine level




	High Osmolality	Low Osmolality		Iso-osmolality
Molecular Structure				
	Ionic monomer	Ionic dimer	Nonionic monomer	Nonionic dimer
Generic Name (mg contrast/ml)	Diatrizoate meglumine and diatrizoate sodium (760)	Ioxaglate meglumine and ioxaglate sodium (589)	lopamidol (408) lopamidol (510) lopamidol (612) lopamidol (755)	Iodixanol (550) Iodixanol (652)
Iodine Concentration (mg/ml)	370	320	200–370	270–320
Osmolality (mOsm/kg H₂O)	1551	~600	413–796	290
Viscosity (mPa·sec at 37°C)	10.5	7.5	2.0–9.4	6.3–11.8

Figure 1. Classification of Available Contrast Agents.
 Contrast agents are classified according to osmolality. Examples of molecular structures and specific agents are shown, and characteristics are described according to the American College of Radiology's *Manual on Contrast Media*.⁸

that has increased by at least 0.3 mg per deciliter (26.5 μmol per liter) over the baseline value within 48 hours after exposure to contrast medium, or a urinary volume of less than 0.5 ml per kilogram of body weight per hour that persists for at least 6 hours after exposure.²² Although the plasma creatinine component of this definition has reasonable sensitivity, its specificity is poor, because plasma creatinine levels fluctuate owing to fluid shifts and medication effects. Since other factors (e.g., medications, hypotension, or atheroemboli) can precipitate acute kidney injury after exposure to contrast medium, the term “contrast-associated acute kidney injury” has gained favor.

The risk of acute kidney injury after the administration of contrast material is also influenced by patient- and procedure-related factors. Preexisting chronic kidney disease is the strongest patient-related risk factor, with lower levels of kidney function associated with higher degrees of risk.²³ An analysis of data from 985,737 patients undergoing percutaneous coronary intervention (PCI) confirmed that severe chronic kidney disease was the strongest independent risk

factor for contrast-associated acute kidney injury.²⁴ Although diabetes mellitus is commonly cited as a risk factor, data from the Iohexol Cooperative Study, performed more than 20 years ago, showed that it was not an independent risk factor but rather amplified susceptibility in patients with underlying chronic kidney disease.²⁵ As compared with the early, high-osmolality contrast agents, low-osmolality and iso-osmolality agents are associated with a lower risk of kidney injury and their use is recommended (class I recommendation, level of evidence A) by the European Society of Cardiology and the American Heart Association–American College of Cardiology.^{25–28} Use of contrast medium at a high volume (>350 ml or >4 ml per kilogram) or repeated administration within 72 hours after initial administration has been shown to be associated with an increased risk.^{18,29}

There is also evidence that the risk of acute kidney injury varies with the clinical presentation and the type of imaging procedure. For example, patients with ST-segment elevation myocardial infarction who undergo PCI have a particularly high risk of contrast-associated kidney injury.³⁰




Figure 2. Proposed Mechanisms of Contrast-Associated Acute Kidney Injury.

Direct mechanisms of kidney injury from exposure to contrast agents are thought to be due to nephrotoxic effects on the tubular epithelium, leading to loss of function, apoptosis, and eventually, necrosis. Such effects are related to the biochemical properties of the particular contrast medium. At the level of the individual nephron, early tubular epithelial injury is characterized by the loss of cell polarity due to the redistribution of Na^+/K^+ -ATPase from the basolateral to the luminal surface of the tubular cells, resulting in abnormal ion transport across the cells and increased sodium delivery to the distal tubules. This phenomenon leads to further renal vasoconstriction through tubuloglomerular feedback. With the progression of cellular injury, epithelial cells detach from the basement membranes and cause luminal obstruction, increased intratubular pressure, and finally, a decrease in the glomerular filtration rate. Indirect effects of contrast agents involve ischemic injury from regionally or globally decreased perfusion. Contrast agents may lead to intrarenal vasoconstriction locally mediated by vasoactive substances such as endothelin, nitric oxide, and prostaglandin, resulting in reduced glomerular blood flow and reduced oxygen delivery to the metabolically active parts of the nephron. In addition, contrast agents increase blood viscosity, leading to further reduction of the microcirculatory flow and to changes in blood osmolality, which in turn impair the plasticity of erythrocytes and may increase the risk of microvascular thrombosis.

It is generally believed that arteriography is associated with a higher risk than computed tomography (CT), owing to delivery of more concentrated contrast material to the kidneys with arteriographic procedures and the higher overall risk profile of patients requiring such procedures.

A series of risk-stratification models that incorporate patient and procedural factors have been validated in past studies (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).^{18,31-34} A strength of these risk-stratification models is that they are derived from data based on large numbers of patients. However, there are caveats to their clinical use — namely, the inclusion of variables (e.g., the volume of contrast material administered and use or nonuse of a hemodynamic-support device) that are unknown before the procedure. Furthermore, most of these models were developed in studies involving patients undergoing PCI, which limits their generalizability.

SERIOUS ADVERSE OUTCOMES
AND IMPLICATIONS FOR CLINICAL
PRACTICE

Many studies have shown that contrast-associated acute kidney injury, defined by small decrements in kidney function, is associated with increased mortality.^{31,35-41} Contrast-associated acute kidney injury is also correlated with accelerated progression of underlying chronic kidney disease. James et al. reported that the risk of a sustained reduction in kidney function at 90 days was greater for patients who had acute kidney injury after undergoing coronary angiography than for those who did not have acute kidney injury.⁴² For patients with mild acute kidney injury, the adjusted odds ratio was 4.7 (95% confidence interval [CI], 3.9 to 5.7), and for those with more severe acute kidney injury, the adjusted odds ratio was 17.3 (95% CI, 12.0 to 24.9), supporting a graded relationship between the severity of acute kidney injury and the risk of sustained kidney impairment. Accordingly, deteriorating kidney function after angiography or angioplasty has been characterized as a major procedural complication in the National Cardiovascular Data Registry.²⁴

Collectively, these studies and others with similar findings undoubtedly raised awareness

of contrast-associated acute kidney injury and spurred research to identify preventive strategies. However, the reports are solely associational (Fig. S1 in the Supplementary Appendix). It is plausible that contrast-associated acute kidney injury is a marker of an increased risk of serious adverse outcomes rather than a mediator of such outcomes. Support for such a view derives from a study by Lassnigg et al.,⁴³ who found that although small postsurgical elevations in plasma creatinine levels were associated with increased 30-day mortality, small decrements in plasma creatinine levels (≤ 0.5 mg per deciliter) were also associated with increased mortality (hazard ratio, 2.27; 95% CI, 1.28 to 4.03). Such fluctuations (up or down) in plasma creatinine levels after surgical or radiographic procedures are probably due to hemodynamic instability, decreased renovascular autoregulation, or both, rather than an actual cause of adverse downstream events. A meta-analysis by Coca et al. showed that interventions that reduced the incidence of acute kidney injury by nearly 50% failed to reduce the risk of longer-term death (relative risk, 0.97; 95% CI, 0.82 to 1.16) or the development of chronic kidney disease (relative risk, 0.87; 95% CI, 0.52 to 1.46).⁴⁴ These observations raise doubt about causation between small increments in plasma creatinine levels after the administration of contrast material and adverse downstream events; they also underscore the problem in defining contrast-associated acute kidney injury on the basis of small increments in a biologic marker (i.e., plasma creatinine) that are neither specific for injury due to the administration of contrast material nor definitively indicative of intrinsic kidney damage. To date, there have been no adequately powered clinical trials showing that prevention of contrast-associated acute kidney injury results in a survival benefit.

Whether contrast-associated acute kidney injury represents a mediator or a marker of adverse outcomes, it appears likely that the many studies documenting these associations have had important unintended consequences for clinical care. A large and growing number of studies have shown that patients with chronic kidney disease are less likely to undergo coronary angiography and revascularization than patients who do not have chronic kidney disease.^{14,45-57} It has been hypothesized that concern about the risk of contrast-associated acute kidney injury explains these

findings. This is of considerable importance, given current uncertainty about the causal relationship between contrast-associated acute kidney injury and serious adverse outcomes, the substantial morbidity and mortality related to cardiovascular disease among patients with chronic kidney disease, and clinical practice guidelines that support the use of invasive care (e.g., angiography) for the management of acute coronary syndromes in most patients with moderate kidney impairment. Studies showing differences in the use of angiography based on the presence or absence of chronic kidney disease underscore the urgent need to determine the true risk of clinically significant acute kidney injury in the large and growing population of patients undergoing contrast-enhanced procedures.

NEPHROTOXICITY OF CONTRAST MATERIAL IN CURRENT PRACTICE

Over the past decade, multiple studies have compared the risk of acute kidney injury after procedures performed with and those performed without intravascular administration of contrast material. A meta-analysis by McDonald et al. that involved 25,950 patients showed no significant difference in the risk of acute kidney injury between patients who underwent procedures with intravenous administration of iodinated contrast material and those who underwent procedures without it (6.4% and 6.5%, respectively; risk ratio, 0.79; 95% CI, 0.62 to 1.02; $P=0.07$).⁵⁸ The incidence rates of dialysis and death were also similar in the two groups. Another meta-analysis showed a lower risk of acute kidney injury among patients with acute ischemic stroke who underwent CT with intravenous administration of contrast material, as compared with patients who underwent CT without the use of contrast material (odds ratio, 0.47; 95% CI, 0.33 to 0.68; $P<0.01$).⁵⁹ Other studies have reported similar findings.^{60,61}

Residual confounding and indication bias are major limitations of such studies. Despite the use of propensity-score matching in some studies, higher-risk patients are less likely to be exposed to contrast material than are lower-risk patients. This likelihood is underscored by the finding in several studies of lower rates of acute kidney injury among patients who were exposed to contrast material than among those who were not,

an observation that should not be construed as indicating a nephroprotective effect of contrast material.^{59,61} These analyses uniformly concluded that intravascular administration of iodinated contrast material does not appear to be associated with an increased risk of acute kidney injury.

Research reveals that the nominal increments in plasma creatinine levels that are used to define acute kidney injury are not uncommon in patients who have undergone contrast-enhanced procedures, nor are such increases uncommon among hospitalized patients in general.^{60,62} However, the incidence of severe acute kidney injury due to contrast material is quite low. A study that prospectively assessed the development of contrast-associated acute kidney injury among patients with chronic kidney disease who were undergoing nonemergency coronary angiography showed that 1.2% of the patients had a postprocedure increase in the plasma creatinine level that was 50% or more of the baseline value, and none had an increase of 100% or more or required dialysis.⁷ In a meta-analysis of studies involving patients who underwent contrast-enhanced CT, the rate of post-procedure dialysis was just 0.3%.⁵⁸ Hence, although currently available data are insufficient to declare that contrast agents are not nephrotoxic, severe acute kidney injury characterized by substantial decrements in kidney function, the need for renal replacement therapy, or both appears to be very infrequent after intravascular contrast administration. Accordingly, a prudent approach to the care of patients undergoing contrast-enhanced procedures involves judicious implementation of evidence-based preventive care for patients identified as being at highest risk for acute kidney injury.

PREVENTIVE STRATEGIES

Research on the prevention of contrast-associated acute kidney injury has focused principally on the use of renal replacement therapies, pharmaceutical agents, and intravenous crystalloid. The benefits of prophylactic renal replacement therapy and of most pharmaceutical agents have not been proved, rendering the provision of periprocedural intravenous crystalloid the primary intervention to mitigate risk. Here we summarize data from studies investigating the use of intravenous fluids and certain pharmaceutical agents to prevent contrast-associated acute kidney injury.

INTRAVASCULAR VOLUME EXPANSION

Although several observational studies have shown a protective effect of intravenous fluids, evidence from randomized clinical trials is relatively sparse. A study by Trivedi et al. that randomly assigned patients undergoing angiography to receive intravenous isotonic saline or unrestricted oral fluids was stopped after 53 patients were enrolled, owing to a markedly lower incidence of contrast-related acute kidney injury with saline (3.7% vs. 34.6%, $P=0.005$).⁶³ Mueller et al. reported a lower rate of contrast-associated acute kidney injury with periprocedural use of isotonic saline as compared with periprocedural use of half-isotonic saline (0.7% vs. 2.0%, $P=0.04$).⁶⁴ However, the patients in this study had a low baseline risk. Current American College of Radiology guidelines on the administration of contrast material recommend the use of intravenous isotonic saline at an infusion rate of 100 ml per hour for 6 to 12 hours before and 4 to 12 hours after angiography.⁸ European Society of Cardiology guidelines on myocardial revascularization recommend intravenous isotonic saline at a rate of 1 to 1.5 ml per kilogram per hour for 12 hours before and up to 24 hours after the procedure.²⁸ A shorter protocol that is more practical for outpatients and those undergoing urgent procedures comprises an intravenous infusion of isotonic saline for 1 to 3 hours before and 6 hours after the procedure.⁶⁵

Despite such recommendations, a recent non-inferiority trial challenged the tenet that intravenous fluids are effective. In the AMACING (A Maastricht Contrast-Induced Nephropathy Guideline) trial, which randomly assigned 660 patients undergoing contrast-enhanced procedures to receive either periprocedural intravenous isotonic saline or no intravenous fluids, there was no significant difference in the incidence of acute kidney injury between the hydration group and the no-hydration group (2.7% and 2.6%, respectively; absolute difference, -0.1 percentage point; 95% CI, -2.25 to 2.06).²¹ However, the validity of this finding is diminished by substantial under-enrollment (although the initial plan was to enroll 1300 patients, only 660 patients underwent randomization), low rates of intraarterial procedures (48%) and interventional procedures (16%), and moderate chronic kidney disease in a majority of patients. Consequently, it is premature to conclude that intravenous fluids are ineffective

or unnecessary on the basis of the results of this trial.

The volume of intravenous fluid necessary for the prevention of acute kidney injury in patients undergoing contrast-enhanced imaging procedures, including those with underlying heart failure, is unknown. The POSEIDON (Prevention of Contrast Renal Injury with Different Hydration Strategies) trial compared standard intravenous administration of fluid with a strategy of fluid administration based on measured left ventricular end-diastolic pressure.²⁰ All patients received 0.9% isotonic saline at a rate of 3 ml per kilogram per hour for 1 hour before undergoing coronary angiography. The control group continued to receive isotonic saline at a rate of 1.5 ml per kilogram per hour during the procedure and for 4 hours afterward, whereas the pressure-guided group received isotonic saline at a rate of 5 ml per kilogram per hour, 3 ml per kilogram per hour, or 1.5 ml per kilogram per hour for left ventricular end-diastolic pressure of less than 13 mm Hg, 13 to 18 mm Hg, and more than 18 mm Hg, respectively. The incidence of acute kidney injury was lower in the pressure-guided group than in the control group (6.7% vs. 16.3%; relative risk, 0.41; 95% CI, 0.22 to 0.79; $P=0.005$), with a very low overall rate of pulmonary compromise.²⁰ Similar results were reported by Qian and colleagues, who used right atrial pressure to guide intravascular volume expansion.⁶⁶ Although volume expansion was associated with an acceptable side-effect profile in these studies, including among patients with clinically significant elevations in filling pressures at baseline, the intravenous fluid and sodium loads may need to be reduced in cases of heart failure or severe hypertension.

Multiple trials, many with small samples, along with subsequent meta-analyses, have compared intravenous isotonic sodium bicarbonate with isotonic sodium chloride for the prevention of contrast-associated acute kidney injury, on the hypothesis that urinary alkalization would reduce contrast-induced generation of injurious oxygen free radicals. The highly divergent results of these trials and resultant clinical equipoise formed the basis for the Prevention of Serious Adverse Events Following Angiography (PRESERVE) study.¹⁹ In a 2-by-2 factorial design, this double-blind trial randomly assigned 5177 high-risk patients undergoing nonemergency angiography

to receive intravenous isotonic sodium bicarbonate or intravenous isotonic saline, as well as oral acetylcysteine or oral placebo, for the prevention of a primary 90-day composite end point comprising death, need for dialysis, or persistent impairment in kidney function. The trial, which was stopped early because of futility, showed no significant difference in the incidence of the primary outcome (4.4% with bicarbonate and 4.7% with saline; odds ratio, 0.93; 95% CI, 0.72 to 1.22; $P=0.62$) or in the incidence of contrast-associated acute kidney injury, which was a secondary end point (9.5% with bicarbonate and 8.3% with saline; odds ratio, 1.16; 95% CI, 0.96 to 1.41; $P=0.13$). Although the exclusion of patients undergoing emergency procedures and a low overall median volume of contrast material administered (85 ml) were limitations of this trial, its large size, robust statistical power, and use of a clinically relevant primary end point were important strengths affirming the investigators' conclusion that isotonic sodium bicarbonate provides no benefit relative to isotonic saline.

ACETYLCYSTEINE

For nearly two decades, numerous clinical trials have investigated the role of acetylcysteine for the prevention of contrast-associated acute kidney injury. The results of these trials and meta-analyses are highly divergent and inconclusive. Despite equipoise on its efficacy, acetylcysteine has been widely used in clinical practice because of its low cost, ease of use, and limited toxic effects. In the PRESERVE trial, oral acetylcysteine was administered at a dose of 1200 mg twice daily for 5 days, beginning on the day of angiography.¹⁹ As compared with placebo, acetylcysteine was not associated with reductions in the rate of death, need for dialysis, or the rate of persistent impairment in kidney function at 90 days (4.6% with acetylcysteine and 4.5% with placebo; odds ratio, 1.02; 95% CI, 0.78 to 1.33; $P=0.88$) or in the rate of contrast-associated acute kidney injury (9.1% and 8.7%, respectively; odds ratio, 1.06; 95% CI, 0.87 to 1.28; $P=0.58$). On the basis of these findings, the routine administration of acetylcysteine is not recommended for the prevention of acute kidney injury or longer-term adverse events after angiographic procedures.

STATINS

The hypothesis that statins reduce the risk of contrast-associated acute kidney injury is based on their antiinflammatory and antioxidant properties. The PROMISS (Prevention of Radiocontrast Medium–Induced Nephropathy Using Short-Term High-Dose Simvastatin in Patients with Renal Insufficiency Undergoing Coronary Angiography) trial failed to show a difference between simvastatin and placebo with respect to a primary end point based on the mean peak increase in the plasma creatinine level within 48 hours after angiography in patients with chronic kidney disease.⁶⁷ Conversely, the PRATO-ACS (Protective Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Acute Kidney Injury and Myocardial Damage in Patients with Acute Coronary Syndrome) trial showed a significant reduction in rates of acute kidney injury and 30-day cardiovascular and renal events after PCI in patients treated with high-dose rosuvastatin (40-mg loading dose on admission followed by a maintenance dose of 20 mg per day) as compared with patients who did not receive statin treatment.⁶⁸

Other trials and several meta-analyses have documented a benefit of prophylactic statins in patients undergoing PCI.^{69,70} However, several of these trials have methodologic limitations — namely, small samples leading to limited statistical power to examine patient-centered outcomes. Further studies are needed to definitively clarify the role of prophylactic administration of high-dose statins. Nonetheless, because high-intensity statins are commonly indicated for atherosclerotic disease according to clinical practice guidelines, many patients undergoing procedures with contrast administration will have an indication for maintenance therapy with these agents.


OTHER PRACTICAL PREVENTIVE CONSIDERATIONS

Among patients identified as high risk, using the lowest necessary total dose of low-osmolality or iso-osmolality contrast medium is advisable. Although a specific threshold definitively associated with contrast-associated acute kidney injury has not yet been determined, one approach is to limit the total volume to less than double the patient's baseline glomerular filtration rate.^{71,72} There are insufficient data to support discontinuation of diuretics, angiotensin-converting–enzyme inhibitors, or angiotensin-receptor blockers. Stop-

ping potentially nephrotoxic agents, including nonsteroidal antiinflammatory medications, is appropriate. A preemptive temporary suspension of metformin therapy has been advocated, not because this medication augments the risk of kidney injury but rather out of concern about the development of lactic acidosis, should severe acute kidney injury occur. Given the prevalence of diabetes, the widespread use of metformin, and practical issues related to the temporary discontinuation of the medication, additional data are needed before firm, evidence-based recommendations can be provided regarding the discontinuation of metformin in patients undergoing contrast-enhanced procedures. Figure 3 depicts our recommended preventive strategies for patients undergoing angiographic procedures.

CONCLUSIONS

There have been incremental advances in our understanding of the pathophysiology of and risk factors for contrast-associated acute kidney injury. However, reliance on a definition based on small increments in the plasma creatinine level, which are frequently transient and nonspecific for contrast-induced damage, coupled with observational studies showing an association with serious, adverse outcomes without known cause, has limited meaningful progress in determining the clinical importance of this condition. Additional work is clearly needed to effectively address the ongoing controversy over the true toxic effects of contrast materials in current use, to determine whether there is any justification for limiting their use in patients at elevated



risk for kidney injury, and to evaluate the possible survival benefit associated with preventing this iatrogenic condition.

The opinions expressed in this article are those of the authors and do not necessarily represent the views of the U.S. government or the Department of Veterans Affairs.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Birgit Vogel, M.D., and Sabato Sorrentino, M.D., Ph.D., at the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, for their help with an earlier draft of the manuscript.

REFERENCES

1. Bartels ED, Brun GC, Gammeltoft A, Gjørup PA. Acute anuria following intravenous pyelography in a patient with myelomatosis. *Acta Med Scand* 1954;150:297-302.
2. Killmann SA, Gjørup S, Thaysen JH. Fatal acute renal failure following intravenous pyelography in a patient with multiple myeloma. *Acta Med Scand* 1957;158:43-6.
3. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. *Radiology* 1993;188:171-8.
4. Swartz RD, Rubin JE, Leeming BW, Silva P. Renal failure following major angiography. *Am J Med* 1978;65:31-7.
5. Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the U.S. Food and Drug Administration. *Radiology* 1997;203:605-10.
6. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism — a critical review. *Am J Kidney Dis* 1994;24:713-27.
7. Weisbord SD, Mor MK, Resnick AL, et al. Prevention, incidence, and outcomes of contrast-induced acute kidney injury. *Arch Intern Med* 2008;168:1325-32.
8. American College of Radiology (ACR) Committee on Drugs and Contrast Media. Manual on contrast media, version 10.2. 2016.
9. McDonald JS, Leake CB, McDonald RJ, et al. Acute kidney injury after intravenous versus intra-arterial contrast material administration in a paired cohort. *Invest Radiol* 2016;51:804-9.
10. McDonald JS, McDonald RJ, Carter RE, Katzberg RW, Kallmes DF, Williamson EE. Risk of intravenous contrast material-mediated acute kidney injury: a propensity score-matched study stratified by baseline-estimated glomerular filtration rate. *Radiology* 2014;271:65-73.
11. McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast material-induced

- nephropathy: causal or coincident phenomenon? *Radiology* 2013;267:106-18.
12. McDonald RJ, McDonald JS, Carter RE, et al. Intravenous contrast material exposure is not an independent risk factor for dialysis or mortality. *Radiology* 2014; 273:714-25.
 13. Bruce RJ, Djamali A, Shinki K, Michel SJ, Fine JP, Pozniak MA. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. *AJR Am J Roentgenol* 2009;192:711-8.
 14. Chertow GM, Normand SL, McNeil BJ. "Renalism": inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. *J Am Soc Nephrol* 2004;15:2462-8.
 15. Heyman SN, Clark BA, Kaiser N, et al. Radiocontrast agents induce endothelin release in vivo and in vitro. *J Am Soc Nephrol* 1992;3:58-65.
 16. Heyman SN, Rosen S, Brezis M. Radiocontrast nephropathy: a paradigm for the synergism between toxic and hypoxic insults in the kidney. *Exp Nephrol* 1994;2: 153-7.
 17. Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. *Clin J Am Soc Nephrol* 2008;3:288-96.
 18. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol* 2004;44:1393-9.
 19. Weisbord SD, Gallagher M, Jneid H, et al. Outcomes after angiography with sodium bicarbonate and acetylcysteine. *N Engl J Med* 2018;378:603-14.
 20. Brar SS, Aharonian V, Mansukhani P, et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial. *Lancet* 2014; 383:1814-23.
 21. Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. *Lancet* 2017;389:1312-22.
 22. Kidney Disease Improving Global Outcomes (KDIGO). Clinical practice guideline for acute kidney injury. *Kidney Int Suppl* 2012;2:1-138.
 23. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. *Am J Cardiol* 2006;98(6A): 27K-36K.
 24. Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI registry. *JACC Cardiovasc Interv* 2014; 7:1-9.
 25. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial: the Iohexol Cooperative Study. *Kidney Int* 1995;47:254-61.
 26. Goldfarb S, Spinler S, Berns JS, Rudnick MR. Low-osmolality contrast media and the risk of contrast-associated nephrotoxicity. *Invest Radiol* 1993;28:Suppl 5: S7-10.
 27. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2014;64(24):e139-e228.
 28. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS guidelines on myocardial revascularization. *Kardiol Pol* 2014; 72:1253-379. (In Polish.)
 29. Maioli M, Toso A, Gallopin M, et al. Preprocedural score for risk of contrast-induced nephropathy in elective coronary angiography and intervention. *J Cardiovasc Med (Hagerstown)* 2010;11:444-9.
 30. Sgura FA, Bertelli L, Monopoli D, et al. Mehran contrast-induced nephropathy risk score predicts short- and long-term clinical outcomes in patients with ST-elevation-myocardial infarction. *Circ Cardiovasc Interv* 2010;3:491-8.
 31. Bartholomew BA, Harjai KJ, Dukkupati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. *Am J Cardiol* 2004;93:1515-9.
 32. Gao YM, Li D, Cheng H, Chen YP. Derivation and validation of a risk score for contrast-induced nephropathy after cardiac catheterization in Chinese patients. *Clin Exp Nephrol* 2014;18:892-8.
 33. Gurm HS, Seth M, Kooiman J, Share D. A novel tool for reliable and accurate prediction of renal complications in patients undergoing percutaneous coronary intervention. *J Am Coll Cardiol* 2013;61: 2242-8.
 34. Tsai TT, Patel UD, Chang TI, et al. Validated contemporary risk model of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the National Cardiovascular Data Registry Cath-PCI Registry. *J Am Heart Assoc* 2014;3(6):e001380.
 35. Levy EM, Viscoli CM, Horwitz RJ. The effect of acute renal failure on mortality: a cohort analysis. *JAMA* 1996;275:1489-94.
 36. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med* 1997;103:368-75.
 37. From AM, Bartholmai BJ, Williams AW, Cha SS, McDonald FS. Mortality associated with nephropathy after radiographic contrast exposure. *Mayo Clin Proc* 2008;83:1095-100.
 38. Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. *J Am Soc Nephrol* 2006;17:2871-7.
 39. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. *J Am Coll Cardiol* 2000;36: 1542-8.
 40. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. *Circulation* 2002; 105:2259-64.
 41. Shema L, Ore L, Geron R, Kristal B. Contrast-induced nephropathy among Israeli hospitalized patients: incidence, risk factors, length of stay and mortality. *Isr Med Assoc J* 2009;11:460-4.
 42. James MT, Ghali WA, Tonelli M, et al. Acute kidney injury following coronary angiography is associated with a long-term decline in kidney function. *Kidney Int* 2010;78:803-9.
 43. Lassnigg A, Schmidlin D, Mouhieddine M, et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. *J Am Soc Nephrol* 2004; 15:1597-605.
 44. Coca SG, Zabetian A, Ferket BS, et al. Evaluation of short-term changes in serum creatinine level as a meaningful end point in randomized clinical trials. *J Am Soc Nephrol* 2016;27:2529-42.
 45. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. *Circulation* 2010; 121:357-65.
 46. Wong JA, Goodman SG, Yan RT, et al. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. *Eur Heart J* 2009;30:549-57.
 47. Lau JK, Anastasius MO, Hyun KK, et al. Evidence-based care in a population with chronic kidney disease and acute coronary syndrome: findings from the Australian Cooperative National Registry of Acute Coronary Care, Guideline Adherence and Clinical Events (CONCORDANCE). *Am Heart J* 2015;170(3):566-72.e1.
 48. Medi C, Montalescot G, Budaj A, et al. Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch

- block: GRACE (Global Registry of Acute Coronary Events). *JACC Cardiovasc Interv* 2009;2:26-33.
49. Chew DP, Amerena JV, Coverdale SG, et al. Invasive management and late clinical outcomes in contemporary Australian management of acute coronary syndromes: observations from the ACACIA registry. *Med J Aust* 2008;188:691-7.
50. Rhee JW, Wiviott SD, Scirica BM, et al. Clinical features, use of evidence-based therapies, and cardiovascular outcomes among patients with chronic kidney disease following non-ST-elevation acute coronary syndrome. *Clin Cardiol* 2014;37:350-6.
51. Saad M, Karam B, Faddoul G, et al. Is kidney function affecting the management of myocardial infarction? A retrospective cohort study in patients with normal kidney function, chronic kidney disease stage III-V, and ESRD. *Int J Nephrol Renovasc Dis* 2016;9:5-10.
52. Han JH, Chandra A, Mulgund J, et al. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. *Am J Med* 2006;119:248-54.
53. Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. *JAMA* 2004;292:2096-104.
54. Nauta ST, van Domburg RT, Nuis RJ, Akkerhuis M, Deckers JW. Decline in 20-year mortality after myocardial infarction in patients with chronic kidney disease: evolution from the prethrombolysis to the percutaneous coronary intervention era. *Kidney Int* 2013;84:353-8.
55. Keough-Ryan TM, Kiberd BA, Dipchand CS, et al. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia. *Am J Kidney Dis* 2005;46:845-55.
56. Goldenberg I, Subirana I, Boyko V, et al. Relation between renal function and outcomes in patients with non-ST-segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome Research and Indicators Collection Project. *Arch Intern Med* 2010;170:888-95.
57. Szummer K, Lundman P, Jacobson SH, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDHEART register. *J Intern Med* 2010;268:40-9.
58. McDonald JS, McDonald RJ, Comin J, et al. Frequency of acute kidney injury following intravenous contrast medium administration: a systematic review and meta-analysis. *Radiology* 2013;267:119-28.
59. Brinjikji W, Demchuk AM, Murad MH, et al. Neurons over nephrons: systematic review and meta-analysis of contrast-induced nephropathy in patients with acute stroke. *Stroke* 2017;48:1862-8.
60. Caspi O, Habib M, Cohen Y, et al. Acute kidney injury after primary angioplasty: is contrast-induced nephropathy the culprit? *J Am Heart Assoc* 2017;6(6): pii:e005715.
61. Wilhelm-Leen E, Montez-Rath ME, Chertow G. Estimating the risk of radiocontrast-associated nephropathy. *J Am Soc Nephrol* 2017;28:653-9.
62. Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. *Am J Nephrol* 2012;35:349-55.
63. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. *Nephron Clin Pract* 2003;93:C29-C34.
64. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. *Arch Intern Med* 2002;162:329-36.
65. Gupta RK, Bang TJ. Prevention of contrast-induced nephropathy (CIN) in interventional radiology practice. *Semin Intervent Radiol* 2010;27:348-59.
66. Qian G, Fu Z, Guo J, Cao F, Chen Y. Prevention of contrast-induced nephropathy by central venous pressure-guided fluid administration in chronic kidney disease and congestive heart failure patients. *JACC Cardiovasc Interv* 2016;9:89-96.
67. Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial — a randomized controlled study. *Am Heart J* 2008;155(3):499.e1-8.
68. Leoncini M, Toso A, Maioli M, et al. Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study. *Am Heart J* 2014;168:792-7.
69. Giacoppo D, Capodanno D, Capranzano P, Aruta P, Tamburino C. Meta-analysis of randomized controlled trials of preprocedural statin administration for reducing contrast-induced acute kidney injury in patients undergoing coronary catheterization. *Am J Cardiol* 2014;114:541-8.
70. Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, Bartorelli AL. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. *Int J Cardiol* 2015;183:47-53.
71. Andò G, de Gregorio C, Morabito G, Trio O, Saporito F, Oretto G. Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention. *Circ Cardiovasc Interv* 2014;7:465-72.
72. Gurm HS, Dixon SR, Smith DE, et al. Renal function-based contrast dosing to define safe limits of radiographic contrast media in patients undergoing percutaneous coronary interventions. *J Am Coll Cardiol* 2011;58:907-14.

Copyright © 2019 Massachusetts Medical Society.

IMAGES IN CLINICAL MEDICINE

The *Journal* welcomes consideration of new submissions for Images in Clinical Medicine. Instructions for authors and procedures for submissions can be found on the *Journal's* website at NEJM.org. At the discretion of the editor, images that are accepted for publication may appear in the print version of the *Journal*, the electronic version, or both.